Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy

Victor Tapias, Shari Jainuddin, Manuj Ahuja, Cliona Stack, Ceyhan Elipenahli, Julie Vignisse, Meri Gerges, Natalia Starkova, Hui Xu, Anatoly A. Starkov, Lucien Bettendorff, Dmitry M. Hushpulian, Natalya A. Smirnova, Irina G. Gazaryan, Navneet A. Kaidery, Sushama Wakade, Noel Y. Calingasan, Bobby Thomas, Gary E. Gibson, Magali Dumont & 1 others M. Flint Beal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced activity of thiaminedependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and transketolase occur in Alzheimer's disease (AD). Thiamine deficiency exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation and oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice. In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, decreased NFTs and prevented death of motor neurons. BFT administration significantly ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/antioxidant response element (ARE)-dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, frontotemporal dementia and progressive supranuclear palsy.

Original languageEnglish (US)
Pages (from-to)2874-2892
Number of pages19
JournalHuman Molecular Genetics
Volume27
Issue number16
DOIs
StatePublished - Jan 1 2018

Fingerprint

Antioxidant Response Elements
Tauopathies
Transgenic Mice
Thiamine
Neurofibrillary Tangles
Alzheimer Disease
Ketoglutarate Dehydrogenase Complex
Transketolase
Thiamine Deficiency
Progressive Supranuclear Palsy
Frontotemporal Dementia
benphothiamine
Amyloid beta-Protein Precursor
Motor Neurons
Pyruvic Acid
Amyloid
Genes
Oxidoreductases
Esters
Oxidative Stress

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Tapias, V., Jainuddin, S., Ahuja, M., Stack, C., Elipenahli, C., Vignisse, J., ... Beal, M. F. (2018). Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Human Molecular Genetics, 27(16), 2874-2892. https://doi.org/10.1093/hmg/ddy201

Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. / Tapias, Victor; Jainuddin, Shari; Ahuja, Manuj; Stack, Cliona; Elipenahli, Ceyhan; Vignisse, Julie; Gerges, Meri; Starkova, Natalia; Xu, Hui; Starkov, Anatoly A.; Bettendorff, Lucien; Hushpulian, Dmitry M.; Smirnova, Natalya A.; Gazaryan, Irina G.; Kaidery, Navneet A.; Wakade, Sushama; Calingasan, Noel Y.; Thomas, Bobby; Gibson, Gary E.; Dumont, Magali; Beal, M. Flint.

In: Human Molecular Genetics, Vol. 27, No. 16, 01.01.2018, p. 2874-2892.

Research output: Contribution to journalArticle

Tapias, V, Jainuddin, S, Ahuja, M, Stack, C, Elipenahli, C, Vignisse, J, Gerges, M, Starkova, N, Xu, H, Starkov, AA, Bettendorff, L, Hushpulian, DM, Smirnova, NA, Gazaryan, IG, Kaidery, NA, Wakade, S, Calingasan, NY, Thomas, B, Gibson, GE, Dumont, M & Beal, MF 2018, 'Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy', Human Molecular Genetics, vol. 27, no. 16, pp. 2874-2892. https://doi.org/10.1093/hmg/ddy201
Tapias, Victor ; Jainuddin, Shari ; Ahuja, Manuj ; Stack, Cliona ; Elipenahli, Ceyhan ; Vignisse, Julie ; Gerges, Meri ; Starkova, Natalia ; Xu, Hui ; Starkov, Anatoly A. ; Bettendorff, Lucien ; Hushpulian, Dmitry M. ; Smirnova, Natalya A. ; Gazaryan, Irina G. ; Kaidery, Navneet A. ; Wakade, Sushama ; Calingasan, Noel Y. ; Thomas, Bobby ; Gibson, Gary E. ; Dumont, Magali ; Beal, M. Flint. / Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. In: Human Molecular Genetics. 2018 ; Vol. 27, No. 16. pp. 2874-2892.
@article{63f2b6e4fb634b0bb375666a14057a50,
title = "Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy",
abstract = "Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced activity of thiaminedependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and transketolase occur in Alzheimer's disease (AD). Thiamine deficiency exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation and oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice. In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, decreased NFTs and prevented death of motor neurons. BFT administration significantly ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/antioxidant response element (ARE)-dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, frontotemporal dementia and progressive supranuclear palsy.",
author = "Victor Tapias and Shari Jainuddin and Manuj Ahuja and Cliona Stack and Ceyhan Elipenahli and Julie Vignisse and Meri Gerges and Natalia Starkova and Hui Xu and Starkov, {Anatoly A.} and Lucien Bettendorff and Hushpulian, {Dmitry M.} and Smirnova, {Natalya A.} and Gazaryan, {Irina G.} and Kaidery, {Navneet A.} and Sushama Wakade and Calingasan, {Noel Y.} and Bobby Thomas and Gibson, {Gary E.} and Magali Dumont and Beal, {M. Flint}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/hmg/ddy201",
language = "English (US)",
volume = "27",
pages = "2874--2892",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy

AU - Tapias, Victor

AU - Jainuddin, Shari

AU - Ahuja, Manuj

AU - Stack, Cliona

AU - Elipenahli, Ceyhan

AU - Vignisse, Julie

AU - Gerges, Meri

AU - Starkova, Natalia

AU - Xu, Hui

AU - Starkov, Anatoly A.

AU - Bettendorff, Lucien

AU - Hushpulian, Dmitry M.

AU - Smirnova, Natalya A.

AU - Gazaryan, Irina G.

AU - Kaidery, Navneet A.

AU - Wakade, Sushama

AU - Calingasan, Noel Y.

AU - Thomas, Bobby

AU - Gibson, Gary E.

AU - Dumont, Magali

AU - Beal, M. Flint

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced activity of thiaminedependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and transketolase occur in Alzheimer's disease (AD). Thiamine deficiency exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation and oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice. In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, decreased NFTs and prevented death of motor neurons. BFT administration significantly ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/antioxidant response element (ARE)-dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, frontotemporal dementia and progressive supranuclear palsy.

AB - Impaired glucose metabolism, decreased levels of thiamine and its phosphate esters, and reduced activity of thiaminedependent enzymes, such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and transketolase occur in Alzheimer's disease (AD). Thiamine deficiency exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation and oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice. In this study, we examined whether BFT confers neuroprotection against tau phosphorylation and the generation of neurofibrillary tangles (NFTs) in the P301S mouse model of tauopathy. Chronic dietary treatment with BFT increased lifespan, improved behavior, reduced glycated tau, decreased NFTs and prevented death of motor neurons. BFT administration significantly ameliorated mitochondrial dysfunction and attenuated oxidative damage and inflammation. We found that BFT and its metabolites (but not thiamine) trigger the expression of Nrf2/antioxidant response element (ARE)-dependent genes in mouse brain as well as in wild-type but not Nrf2-deficient fibroblasts. Active metabolites were more potent in activating the Nrf2 target genes than the parent molecule BFT. Docking studies showed that BFT and its metabolites (but not thiamine) bind to Keap1 with high affinity. These findings demonstrate that BFT activates the Nrf2/ARE pathway and is a promising therapeutic agent for the treatment of diseases with tau pathology, such as AD, frontotemporal dementia and progressive supranuclear palsy.

UR - http://www.scopus.com/inward/record.url?scp=85055345578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055345578&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddy201

DO - 10.1093/hmg/ddy201

M3 - Article

VL - 27

SP - 2874

EP - 2892

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

ER -